DiaMedica Therapeutics Profit Margin 2015-2021 | DMAC
Current and historical gross margin, operating margin and net profit margin for DiaMedica Therapeutics (DMAC) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. DiaMedica Therapeutics net profit margin as of September 30, 2021 is 0%.
|DiaMedica Therapeutics Annual Profit Margins
|DiaMedica Therapeutics Quarterly Profit Margins
||Medical - Biomedical and Genetics
DiaMedica Therapeutics Inc. is a biopharmaceutical company. It engages in the development of novel recombinant proteins and monoclonal antibodies. The companys lead product principally consists DM199, a recombinant human tissue kallikrein-1 protein. It operates primarily in the United States and Canada. DiaMedica Therapeutics Inc. is headquartered in Minneapolis, Minnesota.